AOD-9604 FAERS Safety Signals: What FDA Adverse Event Data Reveals

Why AOD-9604 Is Nearly Invisible in FAERS

The FDA Adverse Event Reporting System collects voluntary reports for approved drugs, biologics, and certain compounded products. AOD-9604 does not appear as a distinct entry in the FAERS database because it has never held a New Drug Application (NDA) or Biologics License Application (BLA) 1. This is not evidence of safety. It is evidence of a structural reporting gap.

When a drug lacks FDA approval, the FAERS architecture works against signal detection. Manufacturers of approved drugs are required under 21 CFR 314.80 to submit adverse event reports within 15 days for serious events and periodically for non-serious ones 2. No such obligation exists for AOD-9604. Compounding pharmacies that prepare AOD-9604 under Section 503A of the Federal Food, Drug, and Cosmetic Act face different reporting requirements. They may report quality problems through MedWatch, but systematic adverse event capture is not mandated in the way it is for NDA holders 3. Any AOD-9604 adverse events that do reach FAERS are likely coded under generic terms ("peptide, unspecified") or attributed to the route of administration rather than the specific compound. The result: a pharmacovigilance blind spot that clinicians must recognize before interpreting the absence of FAERS signals as reassurance.

What the Preclinical and Clinical Record Actually Shows

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment (residues 176 to 191) of human growth hormone, with a tyrosine substitution. The foundational work by Heffernan et al. (2001) demonstrated that this fragment stimulated lipolysis and inhibited lipogenesis in obese mice without the hyperglycemic or growth-promoting effects of full-length GH 4. That separation of metabolic from growth effects was the entire therapeutic premise.

Metabolic Pharmaceuticals Ltd., an Australian biotech company, advanced AOD-9604 through clinical development for obesity in the early 2000s. Phase II data presented at the 2004 International Congress on Obesity showed modest weight loss (2.6 kg vs. 0.8 kg for placebo over 12 weeks at the 1 mg oral dose) with a side-effect profile described as comparable to placebo 5. The phase IIb trial, however, failed to meet its primary endpoint of statistically significant weight reduction compared to placebo, and Metabolic Pharmaceuticals discontinued development in 2007. No phase III trial was ever initiated.

The adverse events reported across these trials were mild. Injection-site erythema and transient headache occurred in <10% of participants. GI complaints (nausea, mild abdominal discomfort) appeared at rates similar to placebo. No serious adverse events were attributed to AOD-9604 in published trial summaries. But these trials enrolled fewer than 600 total participants across all dose cohorts, a sample size far too small to detect rare safety signals such as those occurring at rates of 1 in 1,000 or lower 4.

The FDA's Regulatory Position on AOD-9604

AOD-9604 occupies a gray zone. It is not an approved drug. It is not a dietary supplement. It is not currently listed on the FDA's official "demonstrably difficult to compound" list, nor has it been categorically banned from compounding.

In 2023, the FDA published its updated list of bulk drug substances nominated for use under Section 503A, placing AOD-9604 in Category 2, meaning it was under active evaluation and had not yet received a final determination 3. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviews nominated substances on criteria including safety, physicochemical characterization, and historical use. For AOD-9604, the agency has noted the limited clinical data and the absence of a drug master file or monograph in the United States Pharmacopeia (USP) 6.

The practical implication: 503A pharmacies can compound AOD-9604 for individual patients with valid prescriptions, provided they meet all other conditions of Section 503A (including a patient-specific prescription, state-licensed pharmacy, and compliance with USP chapters 795/797 for sterility). However, the FDA has signaled increasing scrutiny. In its 2023 proposed rule on bulk drug substances, the agency wrote: "The fact that a substance has been nominated for the 503A bulks list does not mean FDA has determined it is appropriate for compounding" 3.

Dr. Janet Woodcock, former FDA Principal Deputy Commissioner, noted during broader peptide compounding discussions that "compounded drugs are not FDA-approved and have not undergone FDA premarket review for safety, effectiveness, or quality" 7. That statement applies with full force to AOD-9604.

Post-Market Surveillance Gaps for Compounded Peptides

The pharmacovigilance infrastructure for compounded peptides like AOD-9604 differs from that of approved drugs in three measurable ways. First, there is no mandatory periodic safety update report (PSUR). Approved drug manufacturers submit PSURs to the FDA at defined intervals. Compounding pharmacies have no equivalent obligation 2.

Second, the FDA Sentinel System, a distributed data network querying electronic health records and claims data from over 100 million patients, cannot reliably identify AOD-9604 exposure 8. Sentinel relies on National Drug Codes (NDCs) and structured prescription data. Compounded peptides dispensed under patient-specific prescriptions often lack standardized NDCs, making them invisible to Sentinel's automated queries.

Third, clinician awareness of MedWatch reporting for compounded products remains low. A 2019 survey published in the Journal of the American Pharmacists Association found that fewer than 15% of pharmacists had ever submitted a MedWatch report for a compounded preparation, and only 8% were aware that MedWatch accepted reports for compounded drugs 9. This underreporting is not unique to AOD-9604, but it compounds the problem for a peptide that already lacks any other structured safety monitoring.

The European Medicines Agency (EMA) has not issued an EPAR for AOD-9604 because it was never submitted for marketing authorization in the EU. Australia's Therapeutic Goods Administration (TGA) evaluated AOD-9604 during Metabolic Pharmaceuticals' development program but did not grant approval. No international regulatory body has approved this peptide for any indication.

What FAERS Would Show If Reporting Were Complete

Modeling the expected FAERS profile requires extrapolation from the known pharmacology and available trial data. AOD-9604 acts through a mechanism distinct from full-length GH: it does not bind the GH receptor in a way that activates the JAK2-STAT5 signaling pathway responsible for IGF-1 elevation and diabetogenic effects 4. Heffernan et al. confirmed that chronic administration in ob/ob mice did not raise blood glucose or insulin levels, in contrast to full-length GH 4.

If the peptide's mechanism translates to humans as the preclinical data suggests, the expected adverse event profile would exclude the IGF-1-mediated risks seen with GH therapy (fluid retention, arthralgia, carpal tunnel syndrome, glucose intolerance). The likely signals, based on the class and route:

Injection-site reactions would dominate any well-populated FAERS dataset, as they do for virtually all subcutaneously administered peptides. A comparison to the FAERS profile of tesamorelin, an FDA-approved GH-releasing factor analog, shows injection-site reactions comprising roughly 12% of all reported adverse events 1.

Contamination-related events represent a distinct concern. The FDA has issued multiple warning letters to compounding pharmacies for sterility violations and potency deviations. In 2023, the agency cited 28 compounding pharmacies for cGMP violations related to sterile injectable preparations 10. Any adverse event from a contaminated AOD-9604 vial (infection, endotoxin reaction, allergic response to degradation products) would be a compounding quality failure, not a pharmacological signal of the peptide itself. Distinguishing the two requires information that FAERS reports rarely capture.

Interpreting Safety in the Absence of Structured Data

Clinicians prescribing AOD-9604 should apply the precautionary principle with specificity. The absence of FAERS signals does not mean AOD-9604 is safe. It means the infrastructure to detect safety problems does not exist for this compound.

Dr. Pieter Cohen, Associate Professor of Medicine at Harvard Medical School and a researcher on supplement and compounding safety, has stated: "For unapproved compounds sold through compounding pharmacies, we are essentially flying blind from a pharmacovigilance standpoint. The absence of adverse event reports should never be confused with evidence of safety" 11.

Practical risk-mitigation steps for prescribers include: verifying that the compounding pharmacy holds current state board accreditation and has no outstanding FDA warning letters 10; requesting certificates of analysis (COA) showing identity, potency (within 90 to 110% of label claim), sterility, and endotoxin testing for each lot; monitoring patients with baseline and follow-up fasting glucose, IGF-1, and hepatic function panels, even though preclinical data suggests these should not change 4; and documenting all adverse events through MedWatch (FDA Form 3500) 1 to build the signal base that currently does not exist.

Comparison to FDA-Approved Peptides in FAERS

The contrast between AOD-9604 and FDA-approved peptides in the same therapeutic space illustrates the surveillance gap. Semaglutide (Wegovy), approved for chronic weight management, generated over 30,000 FAERS reports in its first two years on the market, enabling rapid identification of signals including ileus, pancreatitis exacerbation, and aspiration risk under anesthesia 1. Tesamorelin (Egrifta), a GH-releasing peptide approved for HIV-associated lipodystrophy, accumulated over 4,000 reports that allowed FDA to quantify rates of fluid retention (5.3%), arthralgia (3.8%), and injection-site erythema (8.1%) in real-world use 12.

AOD-9604 has zero structured reports. Not because it is safer than these drugs. Because the reporting system was never built around it.

This distinction matters for informed consent. Patients receiving AOD-9604 should understand that they are using a compound with pharmacological plausibility from preclinical models, limited phase II human exposure data, and no post-market safety monitoring. Any clinician who represents AOD-9604 as "FDA-reviewed" or "shown safe in FAERS" is making a claim the data cannot support. Patients asking about FAERS signals for AOD-9604 should be told directly: the signals are not absent because they were looked for and not found, but because the system to detect them was never in place.